Future Oncology - selected abstracts - ovarian cancer (repost)

Future Oncology - Vol. 9
 December 2013, Vol. 9, No. 12s, Pages 1-1

Foreword

Trabectedin plus pegylated liposomal doxorubicin: the return of a treatment option for ovarian cancer John Clare Future Oncology, December 2013, Vol. 9, No. 12s, Pages 1-1. Citation | Full Text | PDF (197 KB) | PDF Plus(198 KB)   | Reprints & Permissions

Symposium Paper

Introduction: 1 year of silence? Andrés Poveda, Eric Pujade-Lauraine Future Oncology, December 2013, Vol. 9, No. 12s, Pages 3-3. Citation | Full Text | PDF (221 KB) | PDF Plus(222 KB)   | Reprints & Permissions

Trabectedin mechanism of action: what’s new? Maurizio D’Incalci Future Oncology, December 2013, Vol. 9, No. 12s, Pages 5-10. Summary | Full Text | PDF (1476 KB) | PDF Plus(1477 KB)   | Reprints & Permissions

Biology of ovarian cancer and trabectedin mechanism of action Isabelle Ray-Coquard Future Oncology, December 2013, Vol. 9, No. 12s, Pages 11-17. Summary | Full Text | PDF (1472 KB) | PDF Plus(1473 KB)   | Reprints & Permissions

Optimizing treatment of the partially platinum-sensitive ovarian cancer patient Nicoletta Colombo Future Oncology, December 2013, Vol. 9, No. 12s, Pages 19-23. Summary | Full Text | PDF (493 KB) | PDF Plus(494 KB)   | Reprints & Permissions

Discussion: session 1 Jalid Sehouli, Josep M del Campo, Domenica Lorusso Future Oncology, December 2013, Vol. 9, No. 12s, Pages 25-27. Citation | Full Text | PDF (367 KB) | PDF Plus(367 KB)   | Reprints & Permissions

Increasing the chances for platinum-sensitive ovarian cancer patients Antonio González Future Oncology, December 2013, Vol. 9, No. 12s, Pages 29-35. Summary | Full Text | PDF (946 KB) | PDF Plus(947 KB)   | Reprints & Permissions